Posted by Michael Wonder on 17 Jun 2017
European Commission approves elmiron for bladder pain syndrome
12 June 2017 - Europe's first oral medication for the treatment of bladder pain syndrome characterised by glomerulations or Hunner's lesions has been approved.
The European Commission announced EU approval for elmiron. With the marketing authorisation for elmiron, bene-Arzneimittel has Europe's first approved drug therapy for the treatment of bladder pain syndrome characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition. This disease pattern is also known as interstitial cystitis.
